People · Operator
Named in public records as an officer, director or promoter · active 2013–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Treeline Biosciences, Inc. | — | Biotechnology | Growth/Late | $1.1B | $1.9B | 2021 |
| Loxo Oncology, Inc. | — | Biotechnology | Series B | $33.9M | $948.1M | 2013 |
Joshua H. Bilenker at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Joshua H. Bilenker on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David H. Bonita | 2 | 2 |
| Steven H. Elms | 2 | 2 |
| Avi H. Naider | 2 | 2 |
| Kristina H. Burow | 1 | 1 |
| Jeffrey H. Engelman | 1 | 1 |
| Aftab H. Kherani | 1 | 1 |
| Ali H. Satvat | 1 | 1 |
| Dov H. Goldstein | 1 | 1 |
| David H. Schenkein | 1 | 1 |
| James H. Barrett | 1 | 1 |
| Keith H. Flaherty | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.